scholarly journals TGF-β gene polimorphisms as risk factors for asthma control among clinic patients

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Panek Michał ◽  
Stawiski Konrad ◽  
Kuna Piotr
Keyword(s):  
Asthma Control ◽  
Linear Regression Analysis ◽  
Multivariate Linear Regression Analysis ◽  
Analysis Model ◽  
Asthma Control Test ◽  
Bronchial Inflammation ◽  
Selection Of Variables ◽  
Spectrometry Technique ◽  
Act Score ◽  
Tgf Β1

Abstract Background TGF-β and its receptors play a crucial role in asthma pathogenesis, bronchial hyperreactivity, and bronchial remodeling. Expression of isoforms 1–3 of TGFβ cytokine is influenced by tagging polymorphisms in the TGFβ1, TGFβ2 and TGFβ3 gene, and these SNPs may be associated with the risk of asthma development and severity as well as with other diseases. Polymorphic forms of TGF-β1, TGF-β2 and TGF-β3 genes regulate the degree of bronchial inflammation, deterioration of lung functional parameters in spirometry and elevated level of total IgE. All this results in intensification of disease symptoms. According to current GINA 2020 guidelines, the Asthma Control Test (ACT™) should be applied to assess asthma symptoms. Methods An analysis of polymorphisms localized in TGF-β1, TGF-β2 and TGF-β3 genes was conducted on 652 DNA samples with an application of the MassARRAY® system using the mass spectrometry technique MALDI TOF MS. The degree of asthma control was evaluated with ACT™. Results The occurrence of the T / C genotype in rs8109627 (p = 0.0171) in the TGF-β1 gene is significantly associated with a higher ACT result (controlled asthma) in a multivariate linear regression analysis model after using backward stepwise selection of variables. In addition, in the linear model for prediction of ACT score we showed SNP rs8109627 (p = 0.0497) in the TGF-β1 gene (improvement of the disease control - controlled asthma) and rs2796822 (p = 0.0454) in the TGF-β2 gene (deterioration of the diseases control - uncontrolled asthma) significantly modify the degree of asthma control. Discussion We described clinical significance of two SNPs in two genes TGF-β1 and TGF-β2, as yet unknown. We proved that the use of both genotypes and MAC allows to create a moderately correct prognostic model which is about 70% efficient on the entire set of analyzed SNPs in TGF-β1, TGF-β2, and TGF-β3 genes.

scholarly journals TGF-β gene polimorphisms as risk factors for asthma control among clinic patients.

2020 ◽  
Author(s):  
Michał Gabriel Panek ◽  
Konrad Stawiski ◽  
Piotr Bolesław Kuna
Keyword(s):  
Asthma Control ◽  
Linear Regression Analysis ◽  
Multivariate Linear Regression Analysis ◽  
Analysis Model ◽  
Asthma Control Test ◽  
Bronchial Inflammation ◽  
Selection Of Variables ◽  
Spectrometry Technique ◽  
Act Score ◽  
Tgf Β1

Abstract Background: TGF-β and its receptors play a key role in asthma pathogenesis, bronchial hyperreactivity and bronchial remodeling. Expression of isoforms 1–3 of TGFβ cytokine is influenced by tagging polymorphisms in the TGFβ1, TGFβ2 and TGFβ3 gene, and these SNPs may be associated with the risk of asthma development and severity as well as with other diseases. Polymorphic forms of TGF-β1, TGF-β2 and TGF-β3 genes regulate the degree of bronchial inflammation, deterioration of lung functional parameters in spirometry and elevated level of total IgE. All this results in intensification of disease symptoms. According to current GINA 2020 guidelines, the Asthma Control Test (ACT™) should be applied to assess asthma symptoms. Methods: An analysis of polymorphisms localized in TGF-β1, TGF-β2 and TGF-β3 genes was conducted on 652 DNA samples with an application of the MassARRAY® system using the mass spectrometry technique MALDI TOF MS. The degree of asthma control was evaluated with ACT™. Results: The occurrence of the T / C genotype in rs8109627 (p = 0.0171) in the TGF-β1 gene is significantly associated with a higher ACT result (controlled asthma) in a multivariate linear regression analysis model after using backward stepwise selection of variables. In addition, in the linear model for prediction of ACT score we showed SNP rs8109627 (p = 0.0497) in the TGF-β1 gene (improvement of the disease control - controlled asthma) and rs2796822 (p = 0.0454) in the TGF-β2 gene (deterioration of the diseases control - uncontrolled asthma) significantly modify the degree of asthma control. Discussion: We described clinical significance of two SNPs in two genes TGF-β1 and TGF-β2, as yet unknown. We proved that the use of both genotypes and MAC allows to create a moderately correct prognostic model which is about 70% efficient on the entire set of analyzed SNPs in TGF-β1, TGF-β2, and TGF-β3 genes.

scholarly journals TGF-β gene polimorphisms as risk factors for asthma control among clinic patients.

2020 ◽  
Author(s):  
Michał Panek ◽  
Konrad Stawiski ◽  
Piotr Kuna
Keyword(s):  
Asthma Control ◽  
Linear Regression Analysis ◽  
Multivariate Linear Regression Analysis ◽  
Analysis Model ◽  
Asthma Control Test ◽  
Bronchial Inflammation ◽  
Selection Of Variables ◽  
Spectrometry Technique ◽  
Act Score ◽  
Tgf Β1

Abstract Background: TGF-β and its receptors play a key role in asthma pathogenesis, bronchial hyperreactivity and bronchial remodeling. Expression of isoforms 1–3 of TGFβ cytokine is influenced by tagging polymorphisms in the TGFβ1, TGFβ2 and TGFβ3 gene, and these SNPs may be associated with the risk of asthma development and severity as well as with other diseases. Polymorphic forms of TGF-β1, TGF-β2 and TGF-β3 genes regulate the degree of bronchial inflammation, deterioration of lung functional parameters in spirometry and elevated level of total IgE. All this results in intensification of disease symptoms. According to current GINA 2020 guidelines, the Asthma Control Test (ACT™) should be applied to assess asthma symptoms.Methods: An analysis of polymorphisms localized in TGF-β1, TGF-β2 and TGF-β3 genes was conducted on 652 DNA samples with an application of the MassARRAY® system using the mass spectrometry technique MALDI TOF MS. The degree of asthma control was evaluated with ACT™.Results: The occurrence of the T / C genotype in rs8109627 (p = 0.0171) in the TGF-β1 gene is significantly associated with a higher ACT result (controlled asthma) in a multivariate linear regression analysis model after using backward stepwise selection of variables. In addition, in the linear model for prediction of ACT score we showed SNP rs8109627 (p = 0.0497) in the TGF-β1 gene (improvement of the disease control - controlled asthma) and rs2796822 (p = 0.0454) in the TGF-β2 gene (deterioration of the diseases control - uncontrolled asthma) significantly modify the degree of asthma control.Discussion: We described clinical significance of two SNPs in two genes TGF-β1 and TGF-β2, as yet unknown. We proved that the use of both genotypes and MAC allows to create a moderately correct prognostic model which is about 70% efficient on the entire set of analyzed SNPs in TGF-β1, TGF-β2, and TGF-β3 genes.

DYNAMICS OF INFLAMMATORY-CELLULAR PROFILE OF THE INDUCED SPUTUM IN PATIENTS WITH BRONCHIAL ASTHMA AND COLD AIRWAY HYPERRESPONSIVENESS UNDER BASIC ANTI-INFLAMMATORY THERAPY

2016 ◽  
Vol 1 (60) ◽  
pp. 15-22 ◽  
Author(s):  
Приходько ◽  
Anna Prikhodko ◽  
Пирогов ◽  
Aleksey Pirogov ◽  
Перельман ◽  
...  
Keyword(s):  
Lung Function ◽  
Asthma Control ◽  
Airway Hyperresponsiveness ◽  
Good Control ◽  
Induced Sputum ◽  
Asthma Control Test ◽  
Clinical Criteria ◽  
Bronchial Inflammation ◽  
Before And After ◽  
Anti Inflammatory

The character of changes of inflammatory-cellular pattern of bronchial secretion in patients with asthma in association with cold airway hyperresponsiveness (CAHR) under the influence of standard therapy has been studied little. The aim of the present work is to study dynamics of cellular profile, neutrophilic component of bronchial inflammation under the combination therapy of asthmatics with CAHR. 12 asthma patients with CAHR were studied upon the number of cells of the induced sputum (IS), peroxidase, cytolytic and destructive activity of eosinophils and neutrophils in the sputum, lung function and asthma control with the help of questionnaire Asthma Control Test (АСТ) before and after the therapy with the combination of budesonide/formoterol. Before the therapy the patients had a low level of asthma control (14.4±1.2 points of ACT), FEV1 was 87.4±3.3% from predicted values; in IS neutrophils prevailed (26.4±1.7%) over eosinophils (18.5±2.6%); the level of myeloperoxidase (mean cytochemical coefficient) was 65.9±5.4 pixels. After 48 weeks of the observation only in 58% of patients the criteria of good control of asthma and the improvement of lung function were achieved. In IS there was a decrease of eosinophils (11.4±3.2%; p=0.045); the intensiveness of eosinophils and neutrophils cytolysis dropped; intracellular concentration of myeloperoxidase grew (98.2±14.1 pixels; p=0.0637); destructive changes in granulocytes were registered but the number of neutrophils remained high (34.0±8.2%, р=0.34), which was considered as the factor of stable initiation of inflammation and oxidative stress. Thus, the use of anti-inflammatory treatment regime lasting 48 weeks with combination of budesonide/formoterol oriented to achieve clinical criteria of asthma control in patients with CAHR does not allow to achieve correction of the level of neutrophilic inflammatory component. Quantitative index of neutrophils in IS in these patients has prognostic value for the possible loss of achieved asthma control.

scholarly journals Hubungan Kadar Periostin Serum dan Nilai Asthma Control Test pada Pasien Asma di RSUD Dr. Soetomo Surabaya

2018 ◽  
Vol 4 (2) ◽  
pp. 33
Author(s):  
Ni Made Dwita Yaniswari ◽  
Muhammad Amin
Keyword(s):  
Asthma Control ◽  
Matrix Protein ◽  
Extracellular Matrix Protein ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Test ◽  
Uncontrolled Asthma ◽  
Asthma Control Test ◽  
Asthmatic Patients ◽  
Act Score ◽  
Serum Periostin

Background: Asthma is a heterogenous disease composed of various phenotype. Chronic airway inflammation are fundamental features of asthma. The main treatment of asthma is corticosteroid. The administration of inhaled corticosteroids will reduce the inflammatory process in asthma. Even with adequate inhaled corticosteroid treatment, there are still patients who develop symptoms with lower asthma control test score. Periostin is an extracellular matrix protein as the best single systemic biomarker for assessing tissue eosinophilia, airway remodeling in uncontrolled asthma. The objective of this study was to examine whether serum periostin is correlated with ACT in asthmatic patients. Methods: This research was an observational analytical with cross sectional design conducted in outpatient clinic Dr. Soetomo General Hospital Surabaya for 3 months. In total, we found 40 asthmatic patients who were qualified to the inclusion and exclusion criteria as the research samples.  The questionnaire was filled in to assess the Asthma Control Test and venous blood tests to measure serum periostin levels using Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) method. Results: The mean periostin level profile of the sample was 94.82 ± 19.21 ng/ml and the median was 94.7 ng/ml. The average ACT score was 16.55 ± 2.93 with 85% were uncontrolled asthma. The results of the independent t-test showed serum periostin levels and the level of asthma control based on ACT score in asthmatics patients had a significant correlation (p = 0.024). Conclusion: There is a significant correlation between serum periostin levels and ACT score in asthmatic patients.

scholarly journals The impact of using a mobile application to improve asthma patients’ adherence to medication in Jordan

2021 ◽  
Vol 27 (3) ◽  
pp. 146045822110429
Author(s):  
Mohammad K Al-Nawayseh ◽  
Montaha AL-Iede ◽  
Eman Elayeh ◽  
Rima Hijazeen ◽  
Khaled Al Oweidat ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Asthma Control ◽  
Mobile Application ◽  
Intervention Group ◽  
P Value ◽  
Asthma Control Test ◽  
Adherence To Medication ◽  
Asthma Patients ◽  
Act Score ◽  
The Impact

The main aim of this study is to assess the effectiveness of using a developed asthma mobile application to enhance medication adherence in Jordan. Asthma patients visiting outpatient respiratory clinics and using inhalers were recruited. Patients were assigned into two groups: intervention and control. The intervention group was instructed to download and use the application. Asthma control was assessed using Asthma Control Test (ACT) at baseline and at follow-up of 3 months for both groups. A total of 171 patients (control, n = 83, and intervention, n = 88) participated in the study. After 3 months of usage, patients in the intervention group achieved a significant improvement in ACT score compared to control ( p-value <0.05), and reported a significant satisfaction of the application use. Therefore, the asthma mobile application is found as an effective tool to enhance medication adherence in asthma patients.

scholarly journals Pengaruh Teknik Pernapasan Buteyko terhadap ACT

2018 ◽  
Vol 1 (2) ◽  
pp. 47-61
Author(s):  
Marlin Sutrisna ◽  
Emmy H Pranggono ◽  
Titis Kurniawan
Keyword(s):  
Asthma Control ◽  
Control Test ◽  
Act Scores ◽  
Asthma Control Test ◽  
Group Design ◽  
Post Test ◽  
Quasi Experimental ◽  
Act Score ◽  
Post Hoc ◽  
Better Than

This study aims to determine the effect of buteyko breathing technique on asthma control test.The quasi experimental study with the pretest and post test one group design approach involved 14 patients with asthma selected from the Lung Polyclinic of Dr. Hasan Sadikin Bandung with consecutive sampling. Asthma control was collected using time series ACT. The collected data were analyzed descriptively and inferentially with the scale of significance p smaller than 0.05.The results showed a significantly higher mean difference between ACT scores after buteyko breathing technique 19.79 more or less 1.47 with ACT score at week III 17.50 moe or less 1.78 week II 12.64 more or less 1.82, week I 9.57 more or less 1.95, and pretest 7.64 more or less 1.82. Post hoc analysis found the fourth week post test score 19.79 more or less 1.47 significantly better than post test week III 17.50 more or less 1.78, week II 12.64 more or less 1.82, week I 9.57 more or less 1.95, and pretest 7.64 more or less 1.82 in improving asthma control. It was concluded that there was an effect of buteyko breathing technique on asthma control test. Thus, the results of this study become important as a study material for nurses at the Hospital in an effort to increase asthma control test. Keywords: ACT, Breathing Technique, Bronchial Asthma, Buteyko  

Wirksamkeit von Disease-Management-Programmen für Asthma und COPD? Ergebnisse einer Querschnittstudie

Pneumologie ◽  
2020 ◽  
Vol 74 (03) ◽  
pp. 174-182
Author(s):  
F. Kanniess ◽  
K. Krockenberger ◽  
P. Oepen ◽  
R. Hedrich ◽  
D. Olbrich ◽  
...  
Keyword(s):  
Disease Management ◽  
Asthma Control ◽  
Disease Management Programme ◽  
Management Programme ◽  
Randomisierte Studien ◽  
Control Test ◽  
Asthma Control Test ◽  
Fand Sich ◽  
Copd Assessment Test ◽  
Act Score

Zusammenfassung Einleitung Die Wirksamkeit der deutschen Disease-Management-Programme (DMP) Asthma und chronisch obstruktive Lungenerkrankung (COPD) kann mit den gesetzlich vorgeschriebenen Dokumentationen nicht gezeigt werden. Studien mit Vergleichsgruppen sind selten. Ziel war es, in einer Querschnittstudie zu untersuchen, ob sich die Krankheitskontrolle bei Teilnehmern (DMP+) und Nicht-Teilnehmern (DMP–) der DMP Asthma und COPD voneinander unterscheidet. Methoden Die Studie ist eine prospektive, multizentrische Querschnittstudie, die untersucht, inwieweit DMP+-Patienten sich von entsprechenden DMP–-Patienten im Hinblick auf ihre Krankheitskontrolle voneinander unterscheiden. Primärer Endpunkt war die Krankheitskontrolle, gemessen mit dem Asthma-Control-Test™ (ACT) im Studienteil Asthma sowie dem COPD-Assessment-Test™ (CAT) im Studienteil COPD. Ergebnisse Insgesamt wurden 1038 Asthma-Patienten und 846 COPD-Patienten eingeschlossen, je mit etwa 70 % DMP-Teilnehmern. Der ACT-Score war bei den Asthma-DMP+-Patienten höher als bei den DMP– -Patienten (Mittelwertdifferenz 0,86; 95 % KI: 0,29 – 1,43; p = 0,003), allerdings klinisch nicht relevant. Bei COPD-Patienten fand sich ebenfalls kein klinisch relevanter Unterschied in der Krankheitskontrolle (0,52; 95 % KI: – 0,71 – 1,75; p = 0,405). Nur etwa 60 % der Patienten, die seit mindestens einem Jahr in das entsprechende DMP eingeschrieben waren, hatten an einer strukturierten Schulung teilgenommen. Zwischen geschulten und nicht geschulten Patienten fand sich kein Unterschied in der Krankheitskontrolle. Diskussion Es fand sich kein klinisch relevanter Unterschied in der Krankheitskontrolle zwischen DMP+ - und DMP– -Patienten für die DMP Asthma und COPD. International wurde die Wirksamkeit von DMP bei Asthma und COPD in randomisierten Studien nachgewiesen. Auch in Deutschland sollten randomisierte Studien durchgeführt werden, um die Wirksamkeit der DMP Asthma und COPD zu belegen. Registrierung drks.de, DRKS00007664, Registrierungsdatum: 15.01.2015

scholarly journals Novel pharmacist-led intervention secures the minimally important difference (MID) in Asthma Control Test (ACT) score: better outcomes for patients and the healthcare provider

2018 ◽  
Vol 5 (1) ◽  
pp. e000322
Author(s):  
Michela Tinelli ◽  
John White ◽  
Andrea Manfrin
Keyword(s):  
Asthma Control ◽  
Controlled Trial ◽  
Cluster Randomised Controlled Trial ◽  
Published Data ◽  
Minimally Important Difference ◽  
Control Test ◽  
Traffic Light ◽  
Asthma Control Test ◽  
Life Years ◽  
Act Score

IntroductionA key priority in asthma management is achieving control. The Asthma Control Test (ACT) is a validated tool showing a numerical indicator which has the potential to provide a target to drive management. A novel pharmacist-led intervention recently evaluated and introduced in the Italian setting with a cluster randomised controlled trial (C-RCT) showed effectiveness and cost-effectiveness. This paper evaluates whether the intervention is successful in securing the minimally important difference (MID) in the ACT score and provides better health outcomes and economic savings.MethodsClinical data were sourced from 816 adult patients with asthma participating in the C-RCT. The success of the intervention was measured looking at the proportion of patients reaching MID in the ACT score. Different levels of asthma control were grouped according to international guidelines and graded using the traffic light rating system. Asthma control levels were linked to economic (National Health Service (NHS) costs) and quality-adjusted life years outcomes using published data.ResultsThe median ACT score was 19 (partially controlled) at baseline, and 20 and 21 (controlled) at 3-month and 6-month-follow up, respectively (p<0.01). The percentage of patients reaching MID at 3 and 6 months was 15.8% (129) and 19.9% (162), respectively. The overall annual NHS cost savings per 1000 patients attached to the shift towards the MID target were equal to €346 012 at 3 months and increased to €425 483 at 6 months. Health utility gains were equal to 35.42 and 45.12 years in full health gained, respectively.DiscussionThe pharmacist-led intervention secured the MID in the ACT score and provided better outcomes for both patients and providers.

scholarly journals Disease control in patients with asthma and respiratory symptoms (wheezing, cough) during sleep

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Jonathan Doenges ◽  
Elisabeth Kuckuck ◽  
Werner Cassel ◽  
Olaf Hildebrandt ◽  
Andreas Weissflog ◽  
...  
Keyword(s):  
Asthma Control ◽  
Respiratory Symptoms ◽  
Asthma Management ◽  
Objective Evaluation ◽  
Uncontrolled Asthma ◽  
Asthma Control Test ◽  
Asthmatic Patients ◽  
Significant Difference ◽  
Asthma Patients ◽  
Act Score

Abstract Introduction The Global Initiative for Asthma (GINA)-defined criteria for asthma control include questions about daytime symptoms, limitation of activity, nocturnal symptoms, need for reliever treatment and patients’ satisfaction. Patients with nocturnal symptoms like wheezing and cough often suffer from lower sleep quality and impaired daytime performance. The lack of an appropriate method for standardized and objective monitoring of respiratory symptoms leads to difficulties in asthma management. The aim of this study is to present a new method for automated wheeze and cough detection during sleep and to assess the actual level of asthma control by the Asthma Control Test (ACT). Methods Respiratory symptoms like wheezing and cough were recorded with the LEOSound-Monitor for one night in 55 asthmatic patients in their individual domestic setting. Patients were asked to assess their level of asthma subjectively with the ACT. The study consisted of 37 women and 18 men, with a mean age of 41 years, and a mean BMI of 27 kg/m2. Most of the patients had been taking an ICS/LABA combination and would resort to a SABA as their rescue medication. Results 60% of the participants were classed as having controlled, and 40% were classed as having partially- or uncontrolled asthma. During sleep wheezing was found in 8 of the 55 asthma patients (14.5%) and coughing was found in 30 patients (54.5%). The median ACT score in wheezing-patients was 14, while in non-wheezing patients it was 21. Uncontrolled asthma was found in 6 of the 8 wheezing-patients. Coughing versus non-coughing patients did not show a significant difference in the ACT-score (20, 22 respectively). Conclusion Wheezing is a sign of uncontrolled asthma. The ACT-score in wheezing patients is worse compared to patients without wheezing. LEOSound proofed to be a useful tool in providing an objective evaluation of respiratory symptoms, like coughing and wheezing. In clinical practice, this may allow an improvement in asthma therapy.

Alexithymia and asthma

2016 ◽  
Vol 33 (S1) ◽  
pp. S145-S146
Author(s):  
M. Turki ◽  
R. Naoui ◽  
N. Moussa ◽  
S. Sellami ◽  
I. Gassrara ◽  
...  
Keyword(s):  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Negative Impact ◽  
Control Level ◽  
Asthma Control Test ◽  
Cross Sectional ◽  
The Mean ◽  
Act Score ◽  
Tas 20

IntroductionAlexithymia refers to difficulties in verbal expression of emotions, commonly observed in patients with psychosomatic symptoms. In this context, asthma is described as one of psychosomatic diseases.ObjectivesIdentify clinical profile of asthmatic patients and assess the alexithymia level as well as associated factors.MethodsWe conducted a cross-sectional, descriptive and analytic study, including 30 patients followed for asthma at pulmonary outpatient department, Hedi Chaker Hospital, Sfax, Tunisia, during September and October 2015. We collected socio-demographic and clinical characteristics. Asthma control level was assessed by the Asthma Control Test (ACT). Alexithymia was measured using Toronto Alexithymia Scale (TAS 20).ResultsThe mean age was 51 ans. Sex-ratio F/M was 14. The mean duration of disease was 11 years. Long-term control medicines were: inhaled corticosteroids, long-acting beta agonists and theophylline respectively in 86.7%, 33.3% and 26.7%. Two thirds of our patients had a bad therapeutic adherence. The average ACT score was 16.8 points. Asthma was uncontrolled in 1/3 and well controlled in 1/3 of cases. The average TAS 20 score was 64.8 points. Twenty percent of patients were non-alexithymic, 13.3% had a probable alexithymia and 66.7% were alexithymic. This score was positively correlated to bad asthma control (P < 0.001), long term evolution (P = 0.002) and use of inhaled corticoids (P < 0.001). It was inversely correlated to ACT score (P < 0.001).ConclusionOur study shows the high prevalence of alexithymia in patients with asthma and its negative impact in asthma control. Psychological support aiming specifically alexithymic dimension in these patients is indispensable.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Sign in / Sign up

Export Citation Format

Share Document